



ICLG

The International Comparative Legal Guide to:

Patents 2015

5th Edition

A practical cross-border insight into patents law

Published by Global Legal Group, in association with CDR, with contributions from:

Abreu Advogados

Adams & Adams

Anderson Mori & Tomotsune

Armengaud & Guerlain

BARDEHLE PAGENBERG Studio Legale Casucci Ferretti STP

Beuchat, Barros & Pfenniger

Bird & Bird LLP

Bloomfield Advocates & Solicitors

Daniel Advogados

Delacour

Edwards Wildman Palmer LLP

Elzaburu

Fiebinger Polak Leon Attorneys-at-Law

Griffith Hack Lawyers

IP & Law Kancelaria Rzeczników Patentowych

J.Markieta, M.Zielińska-Łazarowicz Sp. Partnerska

Kadasa & Partners

Lee International IP & Law Group

Mehmet Gün & Partners

OLIVARES

Patrinos & Kilimiris

PCK Perry + Currier Inc. | Currier + Kao LLP

Pepeljugoski Law Office

Pham & Associates

REIMANN OSTERRIETH KÖHLER HAFT

Rouse & Co. International

Schellenberg Wittmer Ltd

Subramaniam & Associates

SyCip Salazar Hernandez & Gatmaitan

Tilleke & Gibbins

TIPLO Attorneys-at-Law

Vasil Kisil & Partners

Whitney Moore Solicitors

Wikborg Rein



GLG

Global Legal Group

Contributing Editor
Katharine Stephens,
Bird & Bird LLP

**Head of Business
Development**
Dror Levy

Account Directors
Antony Dine,
Florjan Osmani

Senior Account Managers
Maria Lopez, Oliver Smith,
Rory Smith

Sales Support Manager
Toni Wyatt

Sub Editor
Amy Hirst

Senior Editor
Suzie Levy

Group Consulting Editor
Alan Falach

Group Publisher
Richard Firth

Published by
Global Legal Group Ltd.
59 Tanner Street
London SE1 3PL, UK
Tel: +44 20 7367 0720
Fax: +44 20 7407 5255
Email: info@glgroup.co.uk
URL: www.glgroup.co.uk

GLG Cover Design
F&F Studio Design

GLG Cover Image Source
iStockphoto

Printed by
Ashford Colour Press Ltd.
August 2014

Copyright © 2014
Global Legal Group Ltd.
All rights reserved
No photocopying

ISBN 978-1-910083-13-0
ISSN 2044-3129

Strategic Partners



General Chapters:

1	The New EC Technology Transfer Agreements Block Exemption Regulation – Richard Eccles, Bird & Bird LLP	1
2	Gulf Co-operation Council Countries – Patent Landscape – Sara Holder & Mohammad Jomoa, Rouse & Co. International/Kadasa & Partners (in association with Rouse & Co. International)	6

Country Question and Answer Chapters:

3	Australia	Griffith Hack Lawyers: Wayne Condon & Eliza Jane Mallon	9
4	Austria	Fiebinger Polak Leon Attorneys-at-Law: Constantin Kletzer & Christian Maitz	17
5	Brazil	Daniel Advogados: Rana Gosain	25
6	Canada	PCK Perry + Currier Inc. Currier + Kao LLP: Stephen Perry & Peter Bormann	32
7	Chile	Beuchat, Barros & Pfenniger: Andrés Melossi	38
8	Denmark	Delacour: Johnny Petersen	43
9	France	Armengaud & Guerlain: Catherine Mateu	49
10	Germany	REIMANN OSTERRIETH KÖHLER HAFT: Klaus Haft & Tobias J. Hessel	55
11	Greece	Patrinos & Kilimiris: Constantinos Kilimiris & Tassos Kilimiris	60
12	India	Subramaniam & Associates: Hari Subramaniam	65
13	Ireland	Whitney Moore Solicitors: Aoife Murphy & Robin Hayes	72
14	Italy	BARDEHLE PAGENBERG Studio Legale Casucci Ferretti STP: Giovanni F. Casucci & Niccolò Ferretti	78
15	Japan	Anderson Mori & Tomotsune: Yasufumi Shiroyama & Makoto Ono	84
16	Korea	Lee International IP & Law Group: Seong-Ki Kim & Yoon Suk Shin	90
17	Kosovo	PEPELJUGOSKI CONSULTING L.L.C.: Dr. Valentin Pepeljugin & Ana Pepeljugin	98
18	Macedonia	Pepeljugin Law Office: Dr. Valentin Pepeljugin	105
19	Mexico	OLIVARES: Alejandro Luna & Cesar Ramos, Jr.	112
20	Nigeria	Bloomfield Advocates & Solicitors: Tolushuwa Oyebokun	119
21	Norway	Wikborg Rein: Ingvild Hanssen-Bauer & Lars Erik Steinkjer	125
22	Philippines	SyCip Salazar Hernandez & Gatmaitan: Enrique T. Manuel & Vida M. Panganiban-Alindogan	131
23	Poland	IP & Law Kancelaria Rzeczników Patentowych J. Markieta, M.Zielińska-Łazarowicz Sp. Partnerska: Jarosław Markieta & Małgorzata Zielińska-Łazarowicz	137
24	Portugal	Abreu Advogados: João Veiga Gomes & João Gonçalves Assunção	144
25	Saudi Arabia	Kadasa & Partners (in association with Rouse & Co. International): Sara Holder & Mohammad Jomoa	151
26	South Africa	Adams & Adams: Russell Bagnall & Pieter Visagie	157
27	Spain	Elzaburu: Colm Ahern	165
28	Switzerland	Schellenberg Wittmer Ltd: Andrea Mondini & Philipp Groz	169
29	Taiwan	TIPLo Attorneys-at-Law: J. K. Lin & H. G. Chen	177
30	Thailand	Tilleke & Gibbins: Nandana Indananda & Nuttaphol Arammuang	184
31	Turkey	Mehmet Gün & Partners: Selin Sinem Erciyas & Filiz Toprak Esin	190
32	Ukraine	Vasil Kisel & Partners: Oleksiy Filatov & Tetiana Kudrytska	197
33	UAE	Rouse & Co. International: Sara Holder	204
34	United Kingdom	Bird & Bird LLP: Neil Jenkins & Audrey Horton	209
35	USA	Edwards Wildman Palmer LLP: Ralph Loren	217
36	Vietnam	Pham & Associates: Pham Vu Khanh Toan	223

Further copies of this book and others in the series can be ordered from the publisher. Please call +44 20 7367 0720

Disclaimer

This publication is for general information purposes only. It does not purport to provide comprehensive full legal or other advice. Global Legal Group Ltd. and the contributors accept no responsibility for losses that may arise from reliance upon information contained in this publication. This publication is intended to give an indication of legal issues upon which you may need advice. Full legal advice should be taken from a qualified professional when dealing with specific situations.

Mexico



Alejandro Luna



Cesar Ramos, Jr.

OLIVARES

1 Patent Enforcement

1.1 How and before what tribunals can a patent be enforced against an infringer?

The only venue to enforce a patent is through administrative proceedings (infringement action) before the Mexican Patent Office (IMPI), which is not a Court of Law, but a Federal administrative entity.

1.2 What are the pre-trial procedural stages and how long does it generally take for proceedings to reach trial from commencement?

In Mexico, there is no pre-trial stage or discovery.

1.3 Can a defence of patent invalidity be raised and if so how?

According to the IP Law, a defendant can file an invalidity action against a patent as a counterclaim within the same statutory term to file the response to the infringement action. An independent invalidity action can be filed, but if it is not filed along with the brief of response, it is decided separately from the infringement.

1.4 How is the case on each side set out pre-trial? Is any technical evidence produced and if so how?

All technical evidence is to be filed at the infringement action proceeding or with the invalidity action filed as a counterclaim before the IMPI. The applicable regulations do not contemplate a pre-trial stage, therefore, there is no evidence produced in such a stage.

1.5 How are arguments and evidence presented at the trial? Can a party change its pleaded arguments before and/or at trial?

Arguments should be filed in writing and following applicable procedural rules. All arguments and evidence must be filed along with the initial brief requesting the infringement action, with an exception being provided for supervening evidence. The general rule is no, parties cannot change their pleaded arguments, unless there are supervening or unknown facts.

1.6 How long does the trial generally last and how long is it before a judgment is made available?

The initial stage before the IMPI of a patent infringement action usually takes two years. Once the IMPI issues a decision, the two further stages of appeals before courts lasting no less than three further years are expected.

1.7 Are there specialist judges or hearing officers and if so do they have a technical background?

The IMPI is considered the only authority to solve patent enforcement proceedings in a first instance.

In January 2009, a specialised IP Division at the FCTAA began operating. This Division has jurisdiction to review all cases based on the IPL, the Federal Copyright Act, the Federal Law of Plant Varieties and other IP-related provisions. The creation of this Division should help improve, in general terms, the applicable criteria for IP cases, but the three Magistrates forming this tribunal have no technical background. The last appeal stage is formed by Federal Circuit Magistrates although they are highly capable in legal issues so they do not need to have IP or technical backgrounds.

1.8 What interest must a party have to bring (i) infringement (ii) revocation and (iii) declaratory proceedings?

- I) Any patentee or licensee (unless expressly forbidden from doing so) has the right to prosecute a suit against a third party infringing his or her rights. A distributor may not bring a suit for infringement.
- II) An accused infringer may counterclaim patent invalidity under formal or technical considerations, upon receiving the infringement suit before the IMPI, but it is not possible to request an additional judicial ruling or declaration.
- III) Cease-and-desist letters provide the required legal standing to initiate invalidity actions. If pertaining to a specific industrial or commercial activity (i.e. the pharma industry), to provide legal standing, this is subject to debate and the Courts are divided.
- IV) Amendments to the patent law allow anyone to request the IMPI to initiate officiously the cancellation proceeding against patents.
- V) Simple legal standing, namely the mere business or commercial activity to challenge the validity of patents is under test before the courts.

1.9 Can a party be compelled to provide disclosure of relevant documents or materials to its adversary and if so how?

According to what is set forth in article 192*bis* of the IP Regulation, the IMPI may obtain all the evidence deemed as necessary for the verification of facts that may constitute a violation of one or more of the rights protected by this Act or the administrative declaration procedures.

When the owner concerned or the alleged infringer has submitted sufficient evidence to reasonably have access to support his claims and has specified evidence relevant to the substantiation of its claims that is under the control of the opposing party, the IMPI may order the presentation of such evidence and, where applicable, this authority should ensure the conditions for the protection of confidential information.

1.10 Can a party be liable for infringement as a secondary (as opposed to primary) infringer? Can a party infringe by supplying part of but not all of the infringing product or process?

There is no specific provision in the IP law relating to the doctrine of contributory infringement but there is some room to argue in favour of this doctrine; however it has not been tested before the IMPI or the Courts. Actions may be brought against distributors of an infringing product and provisional measures may be imposed on third parties to some extent.

1.11 Can a party be liable for infringement of a process patent by importing the product when the process is carried on outside the jurisdiction?

Yes, the infringement of a patent in Mexico includes the commercialisation and importation of a product derived from a patented process even if it's carried on outside Mexico.

1.12 Does the scope of protection of a patent claim extend to non-literal equivalents?

It has been interpreted that only literal infringement is recognised under the current IP law. Infringement under the doctrine of equivalence is not expressly provided in the law; a broader interpretation of the patent law to explore the doctrine of equivalents has not been tested before the Mexican Courts.

1.13 Other than lack of novelty and inventive step, what are the grounds for invalidity of a patent?

According to the IP law, patents are valid unless proven otherwise. Thus the IP law establishes several grounds upon which a patent can be invalidated:

- (1) When it was granted in contravention of the provisions on requirements and conditions for the grant of patents or registrations of utility models and industrial designs. Said requirements and conditions for the grant of patents and registrations are those established in articles 16, 19, 27, 31 and 47 of the IP law (novelty, obviousness and utility).
- (2) When it was granted in contravention of the provisions of the law in force at the time when the patent or registration was granted. The nullity action based on this section may not be based on a challenge of the legal representation of the applicant when prosecuting and obtaining a patent or a registration.

- (3) When the application is abandoned during its prosecution.
- (4) When granted by error or serious oversight, or when it is granted to someone not entitled to obtain it. The nullity action mentioned under (1) and (2) may be filed at any time; the actions under (3) and (4) must be filed within five years, counted from the date on which the publication of the patent or registration in the Gazette becomes effective.

1.14 Are infringement proceedings stayed pending resolution of validity in another court or the Patent Office?

Under certain applicable procedural rules, yes however the general rule is to decide linked cases invalidity and infringement simultaneously.

1.15 What other grounds of defence can be raised in addition to non-infringement or invalidity?

Non-infringement

The basis of this defence is that the proper interpretation of the patent claim does not catch the alleged infringing product or process.

Challenging the Validity of Patents

Under the IP law, patents are valid until the contrary is proven.

One of the most common defences in patent litigation in Mexico is to attack the validity of the allegedly infringed patent. As the patent exists, an administrative resolution is required to declare its annulment. This defence must be alleged when replying to the plaintiff's claim, by means of a counterclaim. The IMPI will give notification of the counterclaim to the party who filed the original complaint. Both the infringement claim and the counterclaim should be resolved simultaneously to preclude the possibility of contradictory outcomes. The grounds for invalidating a patent are mentioned in question 1.13.

Fair or Experimental Use

This refers to the non-profit use of the patented invention.

Roche Bolar Exception

In the case of medicines, a party shall be entitled to apply for the registration of a product relating to a substance or active ingredient covered by a patent pertaining to someone else, if the application is filed within three years before the corresponding patent expires. This provision, supported by the "*Roche Bolar Exception*", would allow the applicant to start performing tests and experiments, in order to be ready to enter the market as soon as the patent has expired.

1.16 Are (i) preliminary and (ii) final injunctions available and if so on what basis in each case?

The IP law provides for the possibility of requesting provisional injunctions whereby the IMPI can take certain measures against defendants. These are listed in article 199*bis*.

If the plaintiff chooses to request the IMPI to order a provisional injunction, a bond will be fixed to warrant possible damages to the defendant. This injunction is to be petitioned in writing, and within 20 days from its execution, the plaintiff is required to file a formal written claim of infringement. Failure to do so will cause the plaintiff to lose the bond in favour of the defendant. This party has the right to post a counter-bond to stop the effects of the provisional injunction. Defendants have the right to allege whatever they deem pertinent with respect to the provisional injunctions within a term of 10 days from the date of execution.

The provisional injunctions established by the various sections of article 199*bis* include:

- ordering the recall or impeding circulation of the infringing merchandise;
- ordering the following to be withdrawn from circulation:
 - illegally manufactured or used articles;
 - articles, packaging, wrapping, stationery, advertising material, and other similar items that infringe upon any of the rights protected by law;
 - advertisements, signs, posters, stationery, and other, similar articles that infringe any of the rights protected by law; and
 - utensils or instruments destined for or used in the manufacture, production, or obtainment of any of the concepts indicated in the above sub-bulleted points;
- immediately prohibiting the marketing or use of the products with which any rights protected by the law are violated;
- ordering the attachment of the commodities of the products pursuant to articles 211 to 212*bis*(2); and
- ordering the alleged transgressor or third parties to suspend or cease all acts that constitute a violation of the provisions of the law; and ordering a suspension of service or the closure of the establishment when the measures indicated in the preceding paragraphs are insufficient to prevent or avoid the violation of rights protected by the law.

The IP law establishes that a petitioner of preliminary injunctions will be held responsible for payment of possible damages caused to the party against which said injunctions were implemented, thus the petitioner is requested to post a bond. A defendant is allowed, however, to post a counter-bond to release the preliminary injunctions.

In compliance with article 199*bis* 4 of the IP law, the IMPI will place the bond or counter-bond at the disposal of the party that prevailed on the litigation when the decision of the IMPI becomes final, that is, beyond the shadow of appeal.

1.17 On what basis are damages or an account of profits estimated?

The IP law contemplates a claim for damages and lost profit, in a civil law action. Damages and lost profit start accruing from the date on which the existence of an infringement can be proven. Even though claims for damages involve a lengthy proceeding in addition to the administrative infringement action, the wording of Mexican laws intends to provide fair compensation to the affected party.

Article 221*bis* establishes that the award to the plaintiff in infringement cases cannot be less than 40% of the sale price to the public of each infringing product or service. However, to be allowed to claim damages, the affected title holder must have a final decision beyond the shadow of appeal declaring that the patent was infringed and this proceeding can take years of litigation.

1.18 What other form of relief can be obtained for patent infringement?

Costs and attorneys' fees can be recovered in a civil claim for damages and lost profits. This takes place after the IMPI has declared the administrative infringement. The civil courts follow a specific scheme for reasonable attorneys' fees, regardless of whether this table reflects the actual fees charged.

Criminal sanctions in the event of recidivism are also contemplated in the IP law.

1.19 Are declarations available and if so can they address (i) non-infringement and/or (ii) claim coverage over a technical standard or hypothetical activity?

There are no non-infringement declarations available in the Mexican IP system.

1.20 After what period is a claim for patent infringement time-barred?

The IMPI's current criterion is that the time limit for seeking a remedy is during the life term of the patent. Once the patent has expired, an action may not be brought for events that took place before the end of the life term. A defence of laches has not been tested before the Courts; therefore, legally speaking, a specific time limit exists in the IP Law to bring an infringement action during the life term of the patent.

However, there is a two-year limitation period to pursue a civil action for damages; therefore this statutory term to claim damages should be taken into consideration when looking at the timing to file infringing actions.

1.21 Is there a right of appeal from a first instance judgment and if so is it a right to contest all aspects of the judgment?

Appeals against the IMPI can be brought either before the specialised IP Division of the Federal Administrative Court, or before the IMPI itself through a review recourse. Decisions by either Court can be appealed in a final stage before Federal Circuit Courts.

1.22 What are the typical costs of proceedings to first instance judgment on (i) infringement and (ii) validity; how much of such costs are recoverable from the losing party?

Government fees are minimal in the administration of patent infringements and there are no government costs in the subsequent appeal stages.

Costs and attorneys' fees may be recovered in a civil claim for damages and lost profits as mentioned in question 1.17.

1.23 For countries within the European Union: What steps are being taken in your country towards ratification, implementation and participation in the Unitary Patent Regulation (EU Regulation No. 1257/2012) and the Agreement on a Unified Patent Court? For countries outside of the European Union: Are there any mutual recognition of judgments arrangements relating to patents, whether formal or informal, that apply in your country?

There is no binding mandatory provision in the Mexican legal system that would oblige IMPI and the Mexican Courts to recognise foreign judgments related to patents, this applies for infringement and validity rulings abroad.

However, those decisions in jurisdiction abroad would be evaluated and can be persuasive as documentary evidence.

In some cases, if the factual pattern and evidence are very similar to the case under review in Mexico the case ruled in another jurisdiction may have relevant weight when the case is decided in Mexico.

2 Patent Amendment

2.1 Can a patent be amended *ex parte* after grant and if so how?

According to article 61 of the Industrial Property Law, the text or drawings of a granted patent may only be amended by the patent owner in the following circumstances:

- I. to correct any obvious or form errors; and
- II. to limit the scope of the claims.

The authorised changes shall be published in the Official Gazette.

An amendment after allowance is requested in writing to the Mexican Patent Office, briefly explaining the reasons underlying the errors that are being corrected or the limitations being introduced to the claims.

2.2 Can a patent be amended in *inter partes* revocation proceedings?

In an invalidity action requested by a third party, which may result in a partial nullity of the patent, limiting the scope of the patent, a voluntary amendment would be allowed in an *inter partes* proceeding if both parties agree and if the general rules of the civil law are followed.

2.3 Are there any constraints upon the amendments that may be made?

The amendments are restricted to correct any obvious or form errors, and to limit the scope of the claims.

3 Licensing

3.1 Are there any laws which limit the terms upon which parties may agree a patent licence?

Pursuant to article 63 of the Mexican Industrial Property Law, it is possible to record a licence either onto a granted patent or in a pending application, so that the same may be opposed against third parties.

The limitation to the terms upon which parties may agree a patent licence are found in article 66, which establishes that the term of the licence may not exceed the natural term of the patent itself and may not be recorded when a patent has already elapsed.

Article 67 establishes the chance for the owner to grant further licences unless expressly agreed to the contrary.

It is important to mention that the law indicates that the licensee may exert defensive rights over the patent, unless specifically accorded, while working by licensee inures for the benefit of the licensor.

Finally, in regard to the cancellation of the licence recordal, the Mexican Industrial Property Law establishes that the cancellation occurs when:

- 1) the same should be requested by both the licensee and the licensor jointly;
- 2) the patent lapses or its declared null; or
- 3) by a Court order.

3.2 Can a patent be the subject of a compulsory licence and if so how are the terms settled and how common is this type of licence?

The following provisions of the Mexican Law of Industrial Property are relevant with regard to compulsory licences. Article 70 of the

law states that after three years starting from the date of grant of the patent, or four years from the filing date, whichever is later, anyone may request from the IMPI the grant of a compulsory licence when it has not been used, except if it duly justifies an exit.

The same article also establishes that there will be no grant of a compulsory licence when the holder of the patent or a licensee has been carrying the importation of the patented product or the product obtained by the patented process. Further, article 69 states that the working of a patent by a licensee will be deemed to be worked by its holder, provided that the licence was recorded with the IMPI. Article 71 states that the party applying for a compulsory licence shall have the technical and economical capacity to efficiently work the patented invention.

On the other hand, article 72 establishes that before the grant of the first compulsory licence, the IMPI will provide the patentee with the opportunity to begin working the patent within a term of one year from the date of personal notification given to him. Following a hearing with the parties, the IMPI will decide on the grant of a compulsory licence, and if the IMPI decides to grant it, it will set forth its duration, conditions, field of application and amount of royalties that correspond to the holder of the patent.

We are not aware that any compulsory licence has been granted in the recent years. In any event, the royalties are established by the IMPI after a hearing with the parties and they should be fair and reasonable.

4 Patent Term Extension

4.1 Can the term of a patent be extended and if so (i) on what grounds and (ii) for how long?

The Mexican Regulations do not establish the possibility of patent life term extensions. However, it is important to mention that there are obligations derived from international treaties such as NAFTA which establishes the possibility of patent life term extensions when the Health Authority delays the process to obtain a marketing authorisation for a patented product.

Please note that nobody has tried to obtain a patent life term extension through the application of this possibility regulated by international treaties.

Therefore, in the eventual case that someone would try this kind of action derived from the delay by the Health Authority in the process to obtain a marketing authorisation for a patented product, we consider that it is necessary to argue the direct application of the international treaties as a supremacy law which will in fact rule over domestic law.

Notwithstanding that, the IMPI does not allow an extension on patent terms, as said term extensions are not provided in the Patent Law *per se*; please be advised that our law firm has achieved corrections gaining more time in the expiration date of patents through legal proceedings only for **pipeline patents**, granted in accordance with Transitory Article 12 of the Mexican Law for the Promotion and Protection of Industrial Property Law enacted back in June 1991.

5 Patent Prosecution and Opposition

5.1 Are all types of subject matter patentable and if not what types are excluded?

The following subject matter is not patentable in Mexico:

- I. essentially biological processes for obtaining, reproducing and propagating plants and animals;

- II. biological and genetic material as found in nature;
- III. animal breeds;
- IV. the human body and the living matter constituting it; and
- V. plant varieties.

On the other hand, the following are not considered as inventions in Mexico:

- I. theoretical or scientific principles;
- II. discoveries that consist of making known or revealing something that already existed in nature, even though it was previously unknown to man;
- III. diagrams, plans, rules and methods for carrying out mental processes, playing games or doing business, and mathematical methods;
- IV. computer programmes;
- V. methods of presenting information;
- VI. aesthetic creations and artistic or literary works;
- VII. methods of surgical, therapeutic or diagnostic treatment applicable to the human body and to animals; and
- VIII. juxtaposition of known inventions or mixtures of known products, or alteration of the use, form, dimensions or materials thereof, except where in reality they are so combined or merged that they cannot function separately or where their particular qualities or functions have been so modified as to produce an industrial result or use not obvious to a person skilled in the art.

5.2 Is there a duty to the Patent Office to disclose prejudicial prior disclosures or documents? If so, what are the consequences of failure to comply with the duty?

There is no duty for the IMPI to disclose prejudicial prior art or documents.

5.3 May the grant of a patent by the Patent Office be opposed by a third party and if so when can this be done?

In a period of six months after the publication of the patent application, information related to patentability of an invention can be filed before the IMPI by a third party. If filed, the information may be considered at the Examiner's discretion and it will not suspend the application process. The person filing the information will not be considered a party and will not have access to the patent file or immediate legal standing to challenge a granted patent.

After a patent is granted, anyone can inform the IMPI of causes of invalidity. The authority may consider such information discretionally to initiate an *ex officio* cancellation proceeding.

5.4 Is there a right of appeal from a decision of the Patent Office and if so to whom?

Appeals against decisions of the IMPI can be brought either before a specialised IP Division of the Federal Court for Tax and Administrative Affairs, or before Federal District Judges. Decisions by either court can be appealed in a final stage before Federal Circuit Courts.

5.5 How are disputes over entitlement to priority and ownership of the invention resolved?

Disputes over entitlement to priority and ownership of the invention are resolved by the IMPI. A final decision issued by the IMPI may be appealed (see question 5.4).

5.6 Is there a "grace period" in your country and if so how long is it?

The Mexican Law of Industrial Property contemplates a one-year grace period, as follows:

"**Article 18.** The disclosure of an invention shall not prevent it from continuing to be considered new where, within the 12 months prior to the filing date of the patent application or, where applicable, the recognised priority date, the inventor or his assignee has made the invention known by any means of communication, by putting it into practice or by displaying it at a national or international exhibition. When the corresponding application is filed, the evidentiary documents shall be included in the manner laid down in the Regulations under this law.

The publication of an invention contained in a patent application or in a patent granted by a foreign office shall not be regarded as corresponding to any of the situations referred to in this article."

In order to benefit from the grace period, it is required to file a declaration stating the date, place and means of disclosure, together with the Mexican patent application.

5.7 What is the term of a patent?

The term of a patent is 20 years from the filing date. No extensions of term are available in Mexico.

6 Border Control Measures

6.1 Is there any mechanism for seizing or preventing the importation of infringing products and if so how quickly are such measures resolved?

The Mexican Industrial Property Law establishes that there are available injunctions for infringement of patent rights on a provisional and permanent basis in Mexico. The Customs Law in its articles 148 and 149 establishes the rules for implementing the same with the Mexican Customs.

Generally speaking, in order to grant a preliminary injunction, it is necessary to comply with certain requisites, such as that the holder of the industrial property right has applied to the products, packaging or wrapping of the products protected by the patent, the marking indications, or, by some other means, have made it public knowledge that there is a protected industrial property right.

Other pertinent requisites can be found in article 199*bis* 1, which requires that the requesting party complies with the following as well:

- I. Prove that they hold a patent right and any of the following in addition:
 - a) The existence of an infringement to his right.
 - b) That the infringement to his right will be imminent.
 - c) The existence of the likelihood of irreparable damages suffered.
 - d) The existence of justified fear that the evidence will be destroyed, concealed or altered.
- II. Grant sufficient bond in order to warrant the damages which would be caused to the person against whom the measures are demanded.
- III. Provide the IMPI with the information necessary for the identification of the goods or establishments in which or where the infringement to industrial property rights is occurring.

In regard to the scope of the injunctions, the IMPI may order the alleged infringer or third parties to suspend or discontinue the acts

constituting a violation of the provisions of law and the seizure of goods such as:

1. Objects manufactured or used illegally.
2. Objects, wrappers, containers, packaging, paperwork, advertising material and similar articles that infringe any industrial property right protected by the Industrial Property Law.
3. Signs, labels, tags, paperwork and similar articles that infringe any of the rights protected by the Industrial Property Law.
4. Implements or instruments intended or used for the manufacture, preparation or production of any alleged to infringe relevant industrial property rights. It is important to mention that the alleged infringer is entitled to file a counter-bond to obtain the lifting of the preliminary injunctions.

In regard to the time frame, once the legal requisites are fulfilled, normally preliminary injunctions are adopted and put into practice in a rather fast fashion that may range from two to seven days, depending on the need to implement the same, *i.e.* seizures at customs, due to the nature of the importation process and the need for a rather quick implementation may take 48 hours.

Permanent injunctions are declared once the administrative infringement proceeding is finally decided.

7 Antitrust Law and Inequitable Conduct

7.1 Can antitrust law be deployed to prevent relief for patent infringement being granted?

There is no precedent in Mexico of antitrust, unfair competition or business-related tort actions brought against patentees for the use of a patent. Courts generally consider that the use of a state-given right cannot constitute a violation in these areas.

7.2 What limitations are put on patent licensing due to antitrust law?

An action could theoretically be brought for activities falling outside the scope of a patent, such as non-competition agreements for products that are not covered by the claims, product-tying within that scope, or unfair competition activities such as advertising that a product is better than an alternative for the sole reason of it having a patent. Actions could also be brought before the Antitrust Commission for other forms of abuse of patent rights, such as clearly unfounded attempts to enforce a patent.

8 Current Developments

8.1 What have been the significant developments in relation to patents in the last year?

- **The Mexican Supreme Court ruled on the required legal standing to question marketing authorisations in violation of patents and health law regulations.** The Supreme Court addressed many legal issues relevant for the decision; however, to be concise, we will refer to only some of them, as follows:
 - i) although, it was not the main issue subject of analysis, the Supreme Court states that a patent holder has a subjective right that is transformed in proper legal standing to question any proceeding that may violate its exclusive rights; and
 - ii) in absence of a subjective right such as a patent, based on the human right conferred in the Mexican Constitution to healthcare a pharmaceutical company

having a valid marketing authorisation for an innovative medicine has the proper legal standing to question and request COFEPRIS the issuance of an approval for a bioequivalent product only if it fully complies with all the applicable law and regulations, otherwise the healthcare right provided in the Mexican Constitution would be jeopardised.

Although, this Supreme Court precedent did not order COFEPRIS to cancel the generic approval and also established that COFEPRIS was not bound to call the innovator to the generics approval proceeding, it is a valuable and positive case law which confirms that patent holders have the legal standing to question marketing authorisations that may violate the exclusive rights but also based on the human right to health recognised in the Mexican Constitution, a pharmaceutical company as part of the health system, in order to prevent health risks is entitled to question and request COFEPRIS to observe all the applicable rules and regulations for an approval of a medicine.

■ **Novartis Case in Mexico.**

The Circuit Court ruled on behalf of Novartis considering that Novartis had the proper legal standing to request COFEPRIS to observe the patent listed in the linkage gazette and requested the observance of the Linkage Regulation. In addition, the Circuit Court agreed with the allegation that article 167*bis* of the Linkage Regulation is unconstitutional as it does not provide the right of the titleholder of the patent to be heard during the approval process.

This is the first case in Mexico deciding unconstitutionality against a provision of the Linkage Regulation but on behalf of the patent holder.

As the decision of interest is a final declaration of unconstitutionality of a provision that was applied in prejudice of Novartis, legally speaking, COFEPRIS cannot apply again and in the same manner, this provision against Novartis even in different cases, would mean that derived from this decision, as from now, Novartis is entitled to request participation in “any” approval proceedings by third parties based on article 167*bis* of the Health Regulation that was declared unconstitutional on behalf of Novartis.

8.2 Are there any significant developments expected in the next year?

- New antitrust law under discussion in the Mexican Congress.
- The proposal of the Mexican Patent Law to broaden the scope of compulsory licences.
- The Mexican Government is waiting for the negotiations and eventual execution of the TPP to implement in our domestic law relevant issues regarding patent terms, patent issues, linkage and Patent Data Protection.

8.3 Are there any general practice or enforcement trends that have become apparent in Mexico over the last year or so?

- Patent prosecution highways are becoming more usual.
- Importers of medicines have abused the experimental and Roche Bolar exceptions, now the courts or the corresponding administrative authorities should establish its limits.
- Enforcement of Linkage Regulation on formulations and use patents is a hot topic.
- IP and human rights is a day-to-day argument before the Mexican courts.

**Alejandro Luna**

OLIVARES
Pedro Luis Ogazón # 17, Col. San Ángel
C.P. 01000, Delegación Álvaro Obregón
Mexico City
Mexico

Tel: +52 55 5322 3080
Fax: +52 55 5322 3001
Email: alf@olivares.com.mx
URL: www.olivares.com.mx

Alejandro graduated from the Universidad Latinoamericana, he has obtained IP and Litigation specialisation degrees from the Universidad Panamericana, and a Master's Degree in Intellectual Property Law at the Franklin Pierce Law Centre in Concord, New Hampshire, U.S.A.

He has proactively participated in cases against the unconstitutionality and inefficiency of certain amendments to the Federal Law of Administrative Proceedings in Mexico, which have precipitated challenges to the resolutions by the Mexican Institute of Industrial Property.

Mr. Luna is also the sponsor of a proposal to modify the litigation system of Industrial property, limiting the Mexican Institute of Industrial Property to an exclusive registration authority, transferring the jurisdiction for litigation to Civil Courts in infringement cases, and to Administrative courts for cases related to the annulment of trademark registrations or patents.

Mr. Luna is the author of several articles on patents, litigation and regulatory issues that have been published both in Mexico and abroad. Mr. Luna is a distinguished member of several associations and currently is the Vice-President of the Mexican Association for the Protection of Industrial Property. He was named in the 2007 Guide to the World's Leading Patent Law Practitioners. Currently, Mr. Luna is a partner in charge of the Appeals Department and co-chair of the Life Sciences group at OLIVARES, and he is a part-time professor in the National University (UNAM).

**Cesar Ramos, Jr.**

OLIVARES
Pedro Luis Ogazón # 17, Col. San Ángel
C.P. 01000, Delegación Álvaro Obregón
Mexico City
Mexico

Tel: +52 55 5322 3080
Fax: +52 55 5322 3001
Email: crm@olivares.com.mx
URL: www.olivares.com.mx

Cesar Ramos joined OLIVARES in 1994 and became a partner in 1998. He is the managing partner for the Patent practice group. Prior to joining OLIVARES, Mr. Ramos worked for Telmex, one of the largest telephone and Internet companies in the world, and Monsanto, a global provider of technologies and products for the automotive industry and agriculture. His deep technical knowledge of telecommunications and automotive market coupled with his advanced degree in Engineering positions him as an excellent resource for his clients.

He represents some of the leading innovator companies in the world as he focuses his practice in the areas of telecommunications, electronics, software, energy, diagnostic and medical devices, consumer products and pharmaceuticals. Mr. Ramos' practice is primarily in the area of patent prosecution, but he frequently serves as a technical advisor in litigation support as he brings an expert level of understanding as regards patents.

Education:

B.S., Electrical Engineering, Universidad La Salle, 1987, specialisation in electronics, *with honours*.

M.B.A., Instituto Tecnológico Autónomo de México, 1991, *with honours*.

Associations:

Asociación Mexicana para la Protección de la Propiedad Intelectual (AMPPI) (former Vice-President).

Licensing Executive Society International (LESI) (former Mexican delegate).

American Intellectual Property Law Association (AIPLA).

AIPLA - IP Practice in Latin America Committee.

Asociación Interamericana de la Propiedad Intelectual (ASIFI).

Fédération Internationale Des Conseils En Propriété Intellectuelle (FICPI).

International Association for the Protection of Intellectual Property (AIPPI).

Industry Groups:

Life Science & Pharmaceutical Law Group.

Practice Areas:

Patents.

Licensing & Technology Transfer.

Languages Spoken:

English; Spanish.



OLIVARES

OLIVARES began in 1969 as an intellectual property boutique. Today, the IP Practice serves many different industries, receives numerous awards for excellence in legal service, and leads the charge in protecting clients' valuable IP assets. Whether navigating complex pharmaceutical patent regulations, developing trademark protection strategies, or litigating copyright disputes, OLIVARES gets results.

The award-winning patent attorneys and engineers specialise in the fields of chemistry, biotechnology, pharmacology, mechanics, electronics, computer programmes (software), bioinformatics and nanotechnology, among others, and work with some of the world's largest companies to help secure patent rights in Mexico and across Latin America.

Now, with more than 40 years in business, OLIVARES continues its legacy of excellence in client service and attracts clients from all areas of Mexico in addition to clients from foreign countries needing counsel regarding Mexican laws, regulations and cases.

Current titles in the ICLG series include:

- Alternative Investment Funds
- Aviation Law
- Business Crime
- Cartels & Leniency
- Class & Group Actions
- Competition Litigation
- Construction & Engineering Law
- Copyright
- Corporate Governance
- Corporate Immigration
- Corporate Recovery & Insolvency
- Corporate Tax
- Data Protection
- Employment & Labour Law
- Environment & Climate Change Law
- Franchise
- Gambling
- Insurance & Reinsurance
- International Arbitration
- Lending & Secured Finance
- Litigation & Dispute Resolution
- Merger Control
- Mergers & Acquisitions
- Mining Law
- Oil & Gas Regulation
- Patents
- Pharmaceutical Advertising
- Private Client
- Product Liability
- Project Finance
- Public Procurement
- Real Estate
- Securitisation
- Shipping Law
- Telecoms, Media & Internet
- Trade Marks



59 Tanner Street, London SE1 3PL, United Kingdom
Tel: +44 20 7367 0720 / Fax: +44 20 7407 5255
Email: sales@glgroup.co.uk

www.iclg.co.uk